InspireMD- Warrants Overview
Latest ROE for InspireMD- Warrants: -69.75% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-69.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NSPRZ is -69.75%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside InspireMD- Warrants's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NSPRZ currently prints -69.75% for ROE, while the sector average sits near -100.59%. That is roughly 30.7% above the sector mean. Large gaps often invite a closer look at InspireMD- Warrants's growth, margins, and balance sheet.
Return on Equity shows how effectively InspireMD- Warrants converts resources into returns. At -69.75%, NSPRZ may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NSPRZ's ROE (-69.75%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack InspireMD- Warrants's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
